- Defining what do we do well and what could be improved – EU vs US focus
- Planning and preparation within oncology drug trials – focus on phase 2/3
- Choosing the right trial designs for rare disease studies
- How to achieve a successful launch by building appropriate phase 3
- Chronicles of a site whisperer: Unlocking underperforming trials through connection
- Front-loading focus: Proactive engagement for study success
- Partnership greenhouse: Cultivating strong site relationships
- Safety net navigator: Why escalation pathways matter
- Working with both cooperative groups and biotechs in a harmonious way
- How to streamline processes and improve trial design
- Avoiding pitfalls which can have lasting global impacts
- Setting up trials for offsite patients and ensuring remote data can be obtained
- Navigating new regulations around clinical trials smoothly and successfully
- Predictions for how the global markets will impact US studies
- The impact of artificial intelligence: how far can we expect to move forward in the next 12 months?
- Patient centricity in clinical trials: how can burden be reduced in order to make trials easier for patients to participate in?
- Understanding how we got here
- Coordinating JCA in parallel to MAA
- How to adapt your oncology strategy to JCA
- What’s next for JCA
- What is patient experience data collection and why does it matter?
- Mechanisms for patient engagement across the product development lifecycle
- Demonstrating the value of patient engagement from a variety of perspectives (i.e. biopharmaceutical, patient advocacy, regulatory, and payer)
- Understanding roles and responsibilities for patient advocacy organizations, patient opinion leaders, pharmaceutical sponsors, etc.
